The National Multiple Sclerosis Society has awarded Inflectis BioScience a grant valued at $649,601 to advance the preclinical development of IFB-048, the company’s experimental treatment to promote myelin repair in multiple sclerosis (MS).
“This grant along with the support from the Society are a testimony to the potential of IFB-048 in multiple sclerosis,” Pierre Miniou, PhD, CEO of Inflectis, said in a company press release.
In MS, inflammation in the brain and spinal cord damages the myelin sheath, a fatty covering that wraps around nerve fibers and helps them send electrical signals, sort of like rubber insulation wrapped around a copper wire. Myelin damage results in nerve signaling dysfunction, which gives rise to the symptoms of MS… READ THE FULL STORY HERE.